Why Eli Lilly is a top pick to capitalize on GLP-1 drug craze
As the craze surrounding weight loss drugs like GLP-1s continues, many investors are wondering how to capitalize on the massive valuation given to this sector by many on Wall Street. Matt Higgins, ...
Calls of the Day: Trade Desk, Eli Lilly and Palo Alto Networks
The “Halftime Report” Investment Committee debate the biggest analyst calls of the day.
Eli Lilly Stock's Upside Prompts Morgan Stanley to Ask if It Can Reach $1 Trillion
Morgan Stanley analyst Terence Flynn increases his price target on shares of the drugmaker to $950 from $805.
Eli Lilly's weight-loss drug could be the best selling drug of all time, says Jim Cramer
'Mad Money' host Jim Cramer looks at the top performing stocks on the S&P 500 as it reached the 5,000 milestone.
Call of the Day: Eli Lilly getting a price target boost at Jefferies
Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to to discuss the latest raise to Eli Lilly.
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
Eli Lilly and Novo Nordisk stocks have soared, thanks largely to their weight-loss drugs. However, analysts think that another big pharma stock will perform much better over the near term.
This Unstoppable Growth Stock Just Announced More Good News: Is It a Buy?
Eli Lilly's tirzepatide reported positive phase 2 results in treating a severe disease. The drugmaker may well ride the wave of tirzepatide's successes for a long time.
Could Eli Lilly's Zepbound Become the World's Best-Selling Drug?
Eli Lilly's weight loss drug Zepbound generated more than $175 million in just its first few weeks on the market. The company is addressing a market that could reach $100 billion by 2030, Goldman S...
Lilly Pulitzer CEO talks cost pressures, innovation, new products areas including home and athletic
The most recent University of Michigan Consumer Sentiment Index reading showed a climb in consumer sentiment despite dealing with sticky inflation (prices have not adjusted as quickly to supply and...
Eli Lilly Just Succeeded Where Others Failed, but Does It Matter for the Stock?
A clinical trial for one of Eli Lilly's gene therapy candidates for hearing loss just reported good data. Even if it gets approved eventually, it might not make much money.
Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
Novo Nordisk and Eli Lilly have given positive supply updates, aiming to reassure investors that they can continue to capitalize on the success of their drugs.
Why Shares of Eli Lilly Popped This Week
Eli Lilly just reported strong Q4 earnings. The stock is soaring due to the growth of its weight loss drugs.
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month
Demand is surging for weight-loss treatments that are being rolled out by major pharmaceutical companies. Investors are still trying to assess the full market opportunity and competitive landscape.
4 Reasons Why 2024 Could Be Eli Lilly's Worst Year for the Rest of This Decade
Two of Lilly's top-selling drugs could face challenges this year. Many patients won't have access to the company's biggest growth driver of the future.
The decline in Eli Lilly can be attributed to 'authentic stupidity', says Jim Cramer
'Mad Money' host Jim Cramer talks Eli Lilly, Apple, and action in the markets that doesn't make sense.
Related Companies